Clinical trials: Influenza in Humans
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cancer
Safety Study to Evaluate FluMist in Immunocompromised Children
The main purpose of this study is to get information about the safety of a flu vaccine spray, called FluMist, in children with cancer.
- Trial name
- NCT00112112
- Testing
- FluMist
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- MedImmune LLC
Influenza
Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
This is a randomized clinical trial designed to evaluate the safety/efficacy of two dosing regimens of oral nitazoxanide compared to placebo in the treatment of acute uncomplicated influenza in adults and adolescents.
- Trial name
- NCT01227421
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 624 people
- Sponsor
- Romark Laboratories L.C.
Influenza, Human
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
The purpose of this study is to assess the reactogenicity, safety and immunogenicity of different formulations of GlaxoSmithKline (GSK) Biologicals' investigational supra-seasonal universal influenza vaccines (SUIVs)…
- Trial name
- NCT03275389
- Testing
- D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03
- Where
- 6 sites in United States, Belgium
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Behavior, Health, Flu
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication
This study will be a 6-month, cluster randomized, pragmatic replication trial to evaluate the effectiveness of personalized nudges to clinicians and patients, relative to a control, to increase flu vaccination rates among older…
- Conditions
- Behavior, Health, Flu, Flu Vaccination
- Trial name
- BE IMMUNE Rep (NCT06626321)
- Testing
- Pre-visit patient text messaging, Default pended order, Monthly peer comparison feedback
- Where
- United States
- Volunteers
- 26,248 people
- Sponsor
- University of Pennsylvania
Influenza
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine
This is a phase I study to evaluate the safety of a vaccine to protect against influenza viruses of the H2N2 subtype. A total of 40 adults will be enrolled and receive two doses of vaccine or placebo one month apart.
- Trial name
- NCT01982331
- Testing
- LAIV H2N2
- Where
- Russia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza…
- Trial name
- NCT02141581
- Testing
- Fluzone® (IM), Fluzone® Intradermal (ID), 2011-2012 FluMist®
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.
- Trial name
- NCT00764790
- Testing
- Fluarix, Fluzone
- Where
- 69 sites in United States, Hong Kong and 3 more
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immune Response Following Seasonal Influenza Vaccination
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent…
- Trial name
- NCT03163342
- Testing
- Licensed seasonal influenza vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Influenza
Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00529516
- Testing
- Fluarix, GSK Biologicals Influenza Vaccine GSK576389A
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 1,252 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Respiratory Viral Infections, Human Influenza
Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.
This randomized, single blind clinical study was conducted to investigate the clinical efficacy and safety of the drug Amizon (enisamium iodide), in comparison with placebo for the treatment of patients with acute respiratory…
- Trial name
- NCT04682444
- Testing
- Enisamium Iodide
- Volunteers
- 100 people
- Sponsor
- Joint Stock Company "Farmak"
Influenza
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of…
- Trial name
- MEDI8852 (NCT02603952)
- Testing
- Oseltamivir, MEDI8852
- Where
- 31 sites in United States, South Africa
- Volunteers
- 126 people
- Sponsor
- MedImmune LLC
Rheumatoid Arthritis
Standard Versus High Dose Inactivated Influenza Vaccine in RA
Patients with rheumatoid arthritis have increased risk of seasonal influenza and influenza-related complications but have reduced vaccine immunogenicity.
- Trial name
- IV-RA (NCT02936180)
- Testing
- HD-TIV, SD-QIV
- Where
- Canada
- Volunteers
- 279 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
This randomized, modified double-blind, active-controlled, multi-center trial assessed the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational…
- Trial name
- NCT03282240
- Testing
- QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
- Where
- 36 sites in United States
- Volunteers
- 2,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.
- Trial name
- NCT01003418
- Testing
- GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine, Infanrix™-IPV/Hib, Prevenar
- Where
- 4 sites in Norway
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly
The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).
- Trial name
- NCT00772889
- Testing
- Influenza vaccine GSK2186877A, GSK Biologicals' Fluarix™
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 971 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of pediatric subjects with acute uncomplicated…
- Trial name
- NCT02369159
- Testing
- Peramivir, Oseltamivir
- Where
- 10 sites in United States, South Africa
- Volunteers
- 137 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza
Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
The purpose of this study are to determine the effect FF-3 in comparison to placebo in subjects who are experimentally inoculated with a live, challenge strain of influenza A virus.
- Trial name
- NCT02423577
- Testing
- FF-3 dry powder
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer